Neutralization of HIV-1.
A Workshop on Neutralization of HIV-1: Technology and reagents for analysis of prophylactic vaccines clinical trials, sponsored by the Food and Drug Administration (FDA) and the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), was held on April 19-20, 1993, in Bethesda, Maryland. This workshop brought together researchers who are involved in the development, testing, and evaluation of HIV-1 prophylactic vaccines. The major objectives were (1) to discuss critically the different neutralization and binding assays that are currently used in the evaluation of immune sera; (2) to identify assays that will measure the "most relevant" antibodies, which are likely to predict neutralization of primary isolates; and (3) to identify well-characterized reference reagents, which could be used to standardize neutralization assays used in laboratories around the world.
Golding
H
H
Laboratory of Retrovirus Research, FDA/CBER, Bethesda, Maryland 20892.
D'Souza
M P
MP
Bradac
J
J
Mathieson
B
B
Fast
P
P
D015492:AIDS Serodiagnosis / Q000592:standards*; D016915:AIDS Vaccines / Q000592:standards*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D015497:HIV-1 / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000382:microbiology; D009500:Neutralization Tests; D012015:Reference Standards; D013601:T-Lymphocytes / Q000382:microbiology
D016915:AIDS Vaccines